Skip to main content

Table 3 Matched patient characteristics

From: Clinical benefits of adjuvant chemotherapy with carboplatin and gemcitabine in patients with non-small cell lung cancer: a single-center retrospective study

Matched characteristics CBDCA + GEM (n = 17) CDDP + VNR (n = 17) P
Median age, years (range) 62 (47–70) 59 (33–70) 0.458
Gender (%)    0.243
 Male 14 (82.3) 11 (64.7)  
 Female 3 (17.6) 6 (35.2)  
Surgical procedure (%)    0.367
 Lobectomy 17 (100.0) 16 (94.1)  
 Pneumonectomy 0 1 (5.8)  
ECOG performance status (%)   1
 0 17 (100) 17 (100)  
Pathological stage (%)    0.922
 IIA 2 (11.7) 1 (5.8)  
 IIB 3 (17.6) 4 (23.5)  
 IIIA 8 (47.0) 8 (47.0)  
 IIIB 4 (23.5) 4 (23.5)  
Histology (%)    0.871
 Adenocarcinoma 14 (82.3) 16 (94.1)  
 Squamous cell carcinoma 3 (17.6) 1 (5.8)  
Lymph nodal status (%)    0.513
 N0 4 (23.5) 2 (11.7)  
 N1 2 (11.7) 4 (23.5)  
 N2 11 (64.7) 11 (64.7)  
Number of course    0.434
 1/2/3/4 1/0/1/15 2/0/3/12  
EGFR mutation (%)    0.831
 Negative/unknown 14 (82.3) 13 (76.4)  
 Positive 3(17.6) 4 (23.5)  
ALK fusion (%)    0.310
 Negative/unknown 17(100.0) 16(94.1)  
 Positive 0 1(5.8)  
  1. *P < 0.05